SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Newcourt Acquisition Corp. is a blank check company, which engages in the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded on February 25, 2021 and is headquartered in Oakland, CA.

Psyence Biomedical Ltd.

Psyence Biomedical is experiencing high volatility and intense community discussion following a federal executive order that aims to accelerate research into psychedelic treatments like ibogaine. While retail traders are fueling momentum in anticipation of a potential short squeeze, skepticism remains regarding the stock's long-term fundamentals and the possibility of dilution.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull is trending as retail investors rally behind structural catalysts, specifically the recent termination of a dilution-heavy equity facility and the SEC's removal of pattern day trading restrictions. The community is actively debating potential for a short squeeze and price re-rating, comparing its valuation and platform growth to competitors like Robinhood.

BlackBerry Ltd. engages in the provision of intelligent security software and services. It operates through the following segments: Cybersecurity, Internet of Things (IoT), and Licensing and Other. The Cybersecurity segment includes the brand Cylance, BlackBerry Spark, AtHoc, and SecuSUITE. The IoT segment focuses on software licenses, support, maintenance, and professional services. The Licensing and Other segment involves the intellectual property licensing arrangements and settlement awards. The company was founded by Michael Lazaridis, James Laurence Balsillie, and Douglas E. Fregin on March 7, 1984 and is headquartered in Waterloo, Canada.

BlackBerry Ltd

BlackBerry is surging as investors react to a deepened partnership with NVIDIA that integrates its QNX operating system into industrial AI, robotics, and edge computing platforms. The community is actively discussing the stock's potential for a major valuation re-rate, frequently highlighting the company's transition from a legacy mobile brand into a critical software provider for autonomous systems and the Internet of Things.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is rallying as investors digest news of its upcoming U.S. redomiciliation and potential inclusion in the Russell 2000, while the community actively debates whether the stock is primed for a major short squeeze. Shareholders remain focused on the company's deepening integration into the AI data center supply chain through high-profile partnerships, with many viewing current price action as institutional accumulation despite recent volatility and external short-seller reports.

Avis Budget Group, Inc. engages in the provision of vehicle sharing and rental services. It operates through the Americas and International segments. The Americas segment includes vehicle rental and car sharing operations in North America, South America, Central America, and the Caribbean. The International segment is involved in vehicle rental and car sharing operations in Europe, the Middle East, Africa, Asia, and Australasia. The company was founded in 1946 and is headquartered in Parsippany, NJ.

Avis Budget Group Inc

Avis Budget Group is experiencing a massive, parabolic short squeeze driven by a unique market structure where two major institutional holders effectively control the entire float. The community is actively debating the sustainability of this rally, with many calling it the largest squeeze since GameStop, while cautious traders warn of a potential crash once the company initiates a secondary offering to pay down its significant debt.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

COMPASS Pathways is surging on heavy volume following positive results from its latest Phase 3 trial, which has significantly bolstered investor sentiment and sparked intense discussion regarding the company's path to regulatory approval. Market participants are actively debating the firm's commercial potential and its status as a leader in the psychedelic biotech sector, with many focusing on whether this momentum signals a long-term shift for treatment-resistant depression therapeutics.

Amentum Holdings, Inc. engages in mission-critical, technology-driven services in government and commercial markets. It operates through the Digital Solutions and Global Engineering Solutions segments. The Digital Solutions segment provides advanced digital and data-driven solutions including intelligence analytics, space system development, cybersecurity, and next generation IT. The Global Engineering Solutions segment manages large-scale environmental remediation, nuclear power solutions, platform engineering, sustainment and supply chain management. The company was founded on November 26, 2019 and is headquartered in Chantilly, VA.

Amentum Holdings Inc.

Amentum Holdings is drawing significant community interest as investors weigh its massive backlog of classified government and nuclear infrastructure contracts against recent price volatility ahead of its upcoming earnings report. The discourse centers on the stock acting as a long-term infrastructure play, with many bullish traders actively accumulating shares during price dips while anticipating a major breakout.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is in the spotlight following the FDA approval of Foundayo, a daily oral GLP-1 medication for obesity, signaling a strategic pivot toward expanding its weight-loss platform beyond injectables. Community discussions are highly active, with traders debating the potential for increased market penetration through frictionless oral dosing compared to established competitors, while simultaneously tracking Lilly's aggressive oncology pipeline expansion via recent acquisitions.

Intellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA.

Intellia Therapeutics Inc

Intellia Therapeutics is currently a focal point for investors as the community debates potential short squeeze dynamics driven by high short interest and anticipation surrounding upcoming regulatory and clinical trial updates. Market participants are actively weighing the impact of recent clinical holds against the long-term potential of the company's gene-editing pipeline, leading to volatile price action and heavy discussion regarding institutional accumulation versus short-seller activity.

iShares Inc. - iShares MSCI South Korea ETF

iShares MSCI South Korea ETF

iShares MSCI South Korea ETF is attracting significant investor attention as market participants analyze its heavy concentration in leading memory semiconductor firms, which are benefiting from the sustained demand for high-bandwidth memory in artificial intelligence infrastructure. While the sector faces scrutiny over geopolitical trade relations and tariff threats, the community remains actively focused on the performance of key holdings like Samsung and SK Hynix as proxies for the long-term semiconductor supercycle.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

KROS 2026 Watchlist: 3 Catalysts That Could Reset Sentiment

Keros heads into 2026 with three key catalysts, including DMD study start, ALS regulatory talks, and Takeda progress, that could reshape investor sentiment.

KROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?

Keros reshaped its finances with a Takeda deal, boosting revenue and cutting R&D ??? but does it truly reduce dilution risk as 2026 uncertainty looms?

KROS Rinvatercept: What to Know Before DMD Phase II Starts

KROS sharpens focus on rinvatercept as a phase II DMD study looms in 2026, shifting the story toward execution and high-stakes clinical catalysts.

Keros Therapeutics (NASDAQ:KROS) Director Purchases $11,700.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime acquired 1,000 shares of Keros Therapeutics stock in a transaction dated Wednesday, April 15th. The stock was...

Keros Therapeutics (NASDAQ:KROS) Director Acquires $11,700.00 in Stock

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) Director Jean Jacques Bienaime bought 1,000 shares of the firm's stock in a transaction dated Wednesday, April 15th. The stock was acquired at...

Keros Therapeutics, Inc. (NASDAQ:KROS) Short Interest Down 24.9% in March

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) was the recipient of a large decrease in short interest in March. As of March 31st, there was short interest totaling 1,494,814 shares, a...

Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of "Hold" from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) has been assigned a consensus recommendation of "Hold" from the ten analysts that are presently covering the stock, Marketbeat Ratings...

Keros Therapeutics, Inc. $KROS Shares Acquired by SG Americas Securities LLC

SG Americas Securities LLC lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,420.6% in the fourth quarter, according to its most recent Form 13F filing with the...

JPMorgan Chase & Co. Raises Position in Keros Therapeutics, Inc. $KROS

JPMorgan Chase & Co. grew its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 260.8% during the third quarter, according to the company in its most recent disclosure...

Why Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?

Keros Therapeutics (KROS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Keros Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery, development and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with unmet medical need. The company was founded in 2015 and is headquartered in Lexington, MA.

Current Price	$11.66
Prev Close	$11.67
Open	$11.72
Dividend Yield	0.00%
50-Day Moving Average	$13.00
Beta	0.87
Avg. Volume	573,032.21
PE Ratio	6.40

52-Week High	$22.55
52-Week Low	$10.42
Market Capitalization	$230.1M
EPS (Annual)	$2.30
Price to Book	0.75
Revenue Per Employee	$3.13M

KROS
Keros Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest KROS News

KROSKeros Therapeutics Inc